

## 【消化器内科】

1. Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. *Clin Cancer Res* 2018;24:73-83. (IF:8.911)
2. Nagano H, Obi S, Hatano E, Kaneko S, Kanai F, Omata M, Tsuji A, Itamoto T, Yamamoto K, Tanaka M, Kubo S, Hirata K, Nakamura H, Tomimaru Y, Yamanaka T, Kojima S, Monden M. Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon- $\alpha$  combination therapy for hepatocellular carcinoma with extrahepatic metastases. *Hepato Res* 2018;48:717-726. (IF:3.440)
3. Kojima Y, Hirotsu Y, Omata W, Sugimori M, Takaoka S, Ashizawa H, Nakagomi K, Yoshimura D, Hosoda K, Suzuki Y, Mochizuki H, Omata M. Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. *World J Gastroenterol* 2018;24:511-518. (IF:3.411)
4. Ooka Y, Miho K, Shuntaro O, Nakamura M, Ogasawara S, Suzuki E, Yasui S, Chiba T, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N, Mochizuki H, Omata M. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. *Hepato Int* 2018;12:523-530. (IF:5.490)
5. Wei L, Omata M, Lim YS, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-Oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han KH, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. *Antiviral Res* 2018;158:178-184. (IF:4.130)
6. Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. *Int J Mol Sci* 2018;19:E1940. (IF:4.183)

## 【血液内科】

7. Isoda A, Murayama K, Ito S, Kohara Y, Iino M, Miyazawa Y, Matsumoto M, Handa H, Imai Y, Ishiguro T, Izumita W, Kitano K, Hirabayashi Y, Nakazawa H, Ishida F, Mitsumori T, Kirito K13, Chou T, Murakami H; Kanshinetsu Multiple Myeloma Study Group. Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial. *Int J Hematol* 2018;108:39-46. (IF:2.251)
8. Iino M, Yamamoto T. Efficacy and safety of biosimilar filgrastim for cord blood transplantation: a single-institution retrospective analysis. *Transplant Proc* 2018;50:3804-3810. (IF:0.959)

## 【糖内分泌内科】

9. Nezu M, Kudo M, Morimoto R, Ono Y, Omata K, Tezuka Y, Igarashi Y, Hitachi S, Takase K, Ito S, Satoh F. Effects of surgical treatment for acromegaly on Knee MRI Structural Features. *Endocr J* 2018;65:991-999. (IF:1.940)
10. Takahashi Y, Ota H, Omura K, Dendo Y, Otani K, Matsuura T, Kitami M, Seiji K, Tezuka Y, Nezu M, Ono Y, Morimoto R, Satoh F, Takase K. Image quality and radiation dose of low-tube-voltage CT with reduced contrast media for right adrenal vein imaging. *Eur J Radiol* 2018;98:150-157. (IF:2.948)

## 【呼吸器内科】

11. Iijima Y, Hirotsu Y, Mochizuki H, Amemiya K, Oyama T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Miyashita Y, Omata M. Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer. *Clin Lung Cancer* 2018;19:e843-e847. (IF:4.117)
12. Iijima Y, Fujioka N, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Miyashita Y. Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: A case report. *Int J Infect Dis* 2018;69:75-77. (IF:3.538)

## 【循環器内科】

13. Oka S, Umetani K, Harama T, Shimizu T, Makino A, Sano K, Nakamura M. Cardiac sarcoidosis presenting as acute progressive heart failure with abdominal lymphadenopathy. *Intern Med* 2018;57:511-515. (IF:0.956)
14. Shimizu T, Umetani K, Murata Y, Harama T, Yano T, Makino A, Sano K, Namakura M. Acute myocardial infarction due to simultaneous spasm of 3 coronary arteries that worsened over time. *Am J Emerg Med* 2018;36:528.e3-528.e5. (IF:1.651)

## 【外科】

15. Nakagomi H, Mochizuki H, Inoue M, Hirotsu Y, Amemiya K, Sakamoto I, Nakagomi S, Kubota T, Omata M. Combined Annotation Dependent Depletion (CADD) Score for BRCA1/2 variants in patients with Breast and/or Ovarian Cancer. *Cancer Sci* 2018;109:453-461. (IF:4.751)

## 【呼吸器外科】

16. Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Otake S, Amemiya K, Oyama T, Mochizuki H, Omata M. Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. *Cancers (Basel)* 2018;10:E478. (IF:6.162)
17. Goto T. Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature. *Cancers (Basel)* 2018;10:E223. (IF:6.162)

18. Goto T. What is the best pain control after thoracic surgery? *J Thorac Dis* 2018;9:1335-1338. (IF:2.027)
19. Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Amemiya K, Okimoto K, Oyama T, Mochizuki H, Omata M. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. *Oncotarget* 2018;9:10635-10649.
20. Goto T, Hirotsu Y, Amemiya K, Mochizuki H, Omata M. Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. *Cancers (Basel)* 2018;10:E212. (IF:6.162)
21. Shikata D, Nakagomi T, Higuchi R, Yokoyama Y, Oyama T, Goto T. Lymph node cancer of the mediastinum with a putative necrotic primary lesion in the lung: a case report. *World J Surg Oncol* 2018;16:73. (IF:1.966)
22. Rumi Higuchi, Takahiro Nakagomi, Daichi Shikata, Yujiro Yokoyama, Toshio Oyama, Taichiro Goto. Lingular segmentectomy and left lower lobectomy via unique bronchial dissection. *J Thorac Dis* 2018;10:E420-E425. (IF:2.207)
23. Higuchi R, Goto T, Nakagomi T, Oyama T. Surgery for congenital bronchial atresia. *Asian Cardiovasc Thorac Ann* 2018;26:485-488.

【皮膚科】

24. Kinoshita M, Ogawa Y, Takeichi T, Okamoto T, Osada A, Shimada S, Sugiura K, Akiyama M, Kawamura T, Tsukamoto K. Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab. *Eur J Dermatol* 2018;28:381-382. (IF:3.094)

【婦人科】

25. Sakamoto I, Nakagomi H, Okimoto K, Inoue M, Hirotsu Y, Amemiya K, Mochizuki H, Omata M. Unexpectedly low frequency of BRCA1/2 deleterious mutations in Japanese patients with breast cancer. *Breast J* 2018;24:96-98. (IF:2.433)

【新生児内科】

26. Kobayashi M, Yagasaki H, Kobayashi K, Ogiwara M, Kinouchi H, Sugita K. Xanthogranuloma of the sellar region accompanied by growth hormone deficiency: case report and literature review. *J Pediatr Endocrinol Metab* 2018;31:1161-1164. (IF:1.239)
27. Saito T, Nakane T, Narusawa M, Yagasaki H, Nemoto A, Naito A, Sugita K. Giant umbilical cord and hypoglycemia in an infant with Proteus syndrome. *Am J Med Genet A* 2018;176:1222-1224. (IF:2.197)

【小児外科】

28. Oyachi N, Suzuki S, Emura T, Obana K, Nemoto A, Naito A, Oyama T. Segmental absence of intestinal musculature with metachronous bowel perforations in an infant. *J Pediatr Surg Case Rep* 2018;30:1-3.

【小児循環器病センター】

29. Koizumi K, Hoshiai M, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, Watanabe A, Kagami K, Abe M, Sugita K. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease. *Pediatr Int* 2018;60:796-802. (IF:0.939)
30. Koizumi K, Hoshiai M, Toda T, Nakane T, Sugita K. Marked pleural effusion after i.v. immunoglobulin therapy for Kawasaki disease. *Pediatr Int* 2018;60:307-308. (IF:0.939)
31. Kise H, Ohno S, Kono Y, Yoshizawa M, Harama D, Okafuji A, Toda T, Koizumi K, Hoshiai M, Sugita K, Horie M. Electrical storm in an infant with short-coupled variant of torsade de pointes. *J Arrhythm* 2018;34:315-318.
32. Koizumi K, Hoshiai M, Moriguchi T, Toda T, Katsumata N, Kise H, Hasebe Y, Kono Y, Goto J, Harii N, Matsuda K, Kaga S, Suzuki S, Sugita K. Outcome of plasma exchange for severe dilated cardiomyopathy in children. *Heart Vessels* 2017;32(1):61-67. (IF:1.620)
33. Yagasaki H, Toda T, Koizumi K, Sugiyama T, Ohyama T, Hoshiai M, Nakane T, Sugita K. A de novo 10.1-Mb 3p25 terminal deletion including SETD5 in a patient with ptosis and psychomotor retardation. *Pediatr Neonatol* 2018;59:319-321. (IF:2.326)

【検査部】

34. Amemiya K, Hirotsu Y, Oyama T, Omata M. Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology. *J Vis Exp* 2018;(133). (IF:1.108)

【放射線診断科】

35. Satoh Y, Motosugi U, Saito A, Omiya Y, Onishi H. Pretreatment <sup>18</sup>F-fluorodeoxyglucose Uptake in the Lung Parenchyma Predicts Poor Survival After Stereotactic Body Radiation Therapy in Patients With Stage I Non-Small Cell Lung Cancer. *Technol Cancer Res Treat* 2018;17:1533033818794934. (IF:1.481)

2017 年英文論文

【消化器内科】

1. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017;11:317-370. (IF:5.490)
2. Nishiguchi S, Urano Y, Suzuki K, Taniguchi A, Scherer J, Berger KL, Quinson AM, Stern JO, Omata M. Safety and efficacy of faldaprevir in combination with pegylated interferon  $\alpha$ -2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. *Hepatol Res* 2017;47:E142-E151. (IF:3.440)
3. Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. *Health Qual Life Outcomes* 2017;15:25 (IF:2.318)
4. Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, Bernstien D, Maruyama H, Saraswat V, Chawla Y, Hamid S, Abbas Z, Bedossa P, Sakhuja P, Elmahatab M, Lim SG, Lesmana L, Sollano J, Jia JD, Abbas B, Omar A, Sharma B, Payawal D, Abdallah A, Serwah A, Hamed A, Elsayed A, AbdelMaqsood A, Hassanein T, Ihab A, GHaziuan H, Zein N, Kumar M. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. *Hepatol Int* 2017;11:1-30. (IF:5.490)

【血液内科】

5. Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, Iino M, Isoda A, Nakaya A, Muta T, Miyake T, Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Aoyama T, Sugimori H, Komatsu N. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan. *Blood Cancer J* 2017;7:631. (IF:7.895)

【補内分泌内科】

6. Yu L, Moriguchi T, Kaneko H, Hayashi M, Hasegawa A, Nezu M, Saya H, Yamamoto M, Shimizu R. Reducing Inflammatory Cytokine Production from Renal Collecting Duct Cells by Inhibiting GATA2 Ameliorates Acute Kidney Injury. *Mol Cell Biol* 2017;37:e00211-00217. (IF:3.735)
7. Nezu M, Souma T, Yu L, Sekine H, Takahashi N, Wei AZ, Ito S, Fukamizu A, Zsengeller ZK, Nakamura T, Hozawa A, Karumanchi SA, Suzuki N, Yamamoto M. Nrf2 inactivation enhances placental angiogenesis in a preeclampsia mouse model and improves maternal and fetal outcomes. *Sci Signal* 2017;10:eaam5711. (IF:6.481)
8. Nezu M, Suzuki N, Yamamoto M. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression. *Am J Nephrol* 2017;45:473-483. (IF:2.961)
9. Yu L, Takai J, Otsuki A, Katsuoaka F, Suzuki M, Katayama S, Nezu M, Engel JD, Moriguchi T, Yamamoto M. Derepression of the DNA methylation machinery of Gata1 gene triggers the differentiation cue for erythropoiesis. *Mol Cell Biol* 2017;37:e00592-16. (IF:3.735)
10. Nezu M, Souma T, Yu L, Suzuki T, Saigusa D, Ito S, Suzuki N, Yamamoto M. Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. *Kidney Int* 2017;91:387-401. (IF:8.306)

【呼吸器内科】

11. Miyashita Y, Hirotsu Y, Tsutsui T, Higashi S, Sogami Y, Kakizaki Y, Goto T, Amemiya K, Oyama T, Omata M. Analysis of significantly mutated genes as a clinical tool for the diagnosis in a case of lung cancer. *Respir Med Case Rep* 2017;171-175.
12. Iijima Y, Hirotsu Y, Amemiya K, Higashi S, Miyashita Y, Omata M. Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. *Respir Med Case Rep* 2017;22:31-33.
13. Iijima Y, Hirotsu Y, Amemiya K, Ooka Y, Mochizuki H, Oyama T, Nakagomi T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Goto T, Miyashita Y, Omata M. Very Early Response of Circulating Tumor Derived DNA in Plasma Predict the Efficacy of Treatment by Nivolumab in Patients with Non-small Cell Lung Cancer. *Eur J Cancer* 2017;86:349-357. (IF:6.680)

【循環器内科】

14. Arumugam S, Sreedhar R, Karuppagounder V, Harima M, Nakamura M, Suzuki H, Sone H, Watanabe K. Comparative evaluation of torsemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy. *Cardiovasc Ther* 2017;35. (IF:2.315)
15. Watanabe-K, Sreedhar R, Thandavarayan RA, Karuppagounder V, Giridharan VV, Antony S, Harima M, Nakamura M, Suzuki K, Suzuki H, Sone H, Arumugam S. Comparative effects of torsemide and furosemide on gap junction proteins and cardiac fibrosis in a rat model of dilated cardiomyopathy. *Biofactors* 2017;43:187-194. (IF:3.598)

【外科】

16. Nakagomi H, Hirotsu Y, Okimoto K, Sakamoto I, Amemiya K, Nakagomi S, Kubota T, Mochizuki H, Omata M. PALB2 mutation in a woman with bilateral breast cancer: A case report. *Mol Clin Oncol* 2017;6:556-560.
17. Watanabe H, Miyasaka Y, Watanabe K, Sakamoto I, Nakagomi N, Takano A, Ikegame K, Yamamoto A, Nakada N, Yasutome M, Furuya K, Hada M, Inoue M, Oyama T. Pseudomyxoma peritonei due to low-grade appendiceal mucinous neoplasm with symptoms of inguinal hernia and uterine prolapse: a case report and review of the literature. *Int Cancer Conf J* 2017;6:158-163.
18. Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, Yamamoto A, Takano A, Miyasaka Y, Yasutome M, Hada M, Omata M. Periaortitis induced by epirubicin and cyclophosphamide for a patient with advanced breast cancer. *Int Cancer Conf J* 2017;6:180-183.
19. Nakagomi H, Hirotsu Y, Amemiya K, Nakada H, Inoue M, Mochizuki H, Oyama T, Omata M. Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report. *Am J Case Rep* 2017;18:26-32.
20. Nakada H, Nakagomi H, Hirotsu Y, Amemiya K, Mochizuki H, Inoue M, Oyama T, Omata M. A study of tumor heterogeneity in a case with breast cancer. *Breast Cancer* 2017;24:483-489. (IF:2.044)
21. Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, Omata M, Oyama T. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. *Breast Cancer* 2017;24:667-672. (IF:2.044)
22. Iimuro Y. ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images. *Visc Med* 2017;33:449-454. (IF:1.989)
23. Takano A, Hirotsu Y, Amemiya K, Nakagomi H, Oishi N, Oyama T, Mochizuki H, Omata M. Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report. *Oncol Lett* 2017;14:4428-4432. (IF:1.871)

【呼吸器外科】

24. Yokoyama Y, Nakagomi T, Shikata D, Goto T. Combined analgesic treatment of epidural and paravertebral block after thoracic surgery. *J Thorac Dis* 2017;9:1651-1657. (IF:2.027)
25. Goto T, Hirotsu Y, Amemiya K, Nakagomi T, Shikata D, Yokoyama Y, Okimoto K, Oyama T, Mochizuki H, Omata M. Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood. *Oncotarget* 2017;8:59268-59281.
26. Goto T, Hirotsu Y, Nakagomi T, Shikata D, Yokoyama Y, Amemiya K, Tsutsui T, Kakizaki Y, Oyama T, Mochizuki H, Miyashita Y, Omata M. Detection of tumor-derived DNA dispersed in the airway improves the diagnostic accuracy of bronchoscopy for lung cancer. *Oncotarget* 2017;8:79404-79413.
27. Goto T, Hirotsu Y, Mochizuki H, Nakagomi T, Shikata D, Yokoyama Y, Oyama T, Amemiya K, Okimoto K, Omata M. Mutational

- analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile. *Oncotarget* 2017;8:31133-31143.
28. Yokoyama Y, Nakagomi T, Shikata D, Goto T. A novel technique for chest drain removal using a two layer method with triclosan-coated sutures. *J Thorac Dis* 2017;9:211-213. (IF:2.027)
  29. Nakagomi T, Goto T, Hirotsu Y, Shikata D, Amemiya K, Oyama T, Mochizuki H, Omata M. Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer. *J Thorac Dis* 2017;9:E598-E604. (IF:2.027)
  30. Yokoyama Y, Nakagomi T, Shikata D, Higuchi R, Oyama T, Goto T. Surgical treatment for mediastinal abscess induced by endobronchial ultrasound-guided transbronchial needle aspiration: a case report and literature review. *World J Surg Oncol* 2017;15:130. (IF:1.3966)
  31. Shikata D, Nakagomi T, Yokoyama Y, Yamada Y, Nakajima M, Oyama T, Goto T. Debulking surgery for venous hemangioma arising from the epicardium: report of a case. *World J Surg Oncol* 2017;15:81. (IF:1.3966)
  32. Goto T, Hirotsu Y, Mochizuki H, Nakagomi T, Oyama T, Amemiya K, Omata M. Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report. *BMC Cancer* 2017;17:65. (IF:2.933)
- 【整形外科】
33. Sadatsuki R, Kaneko H, Futami I, Kinoshita M, Hada S, Goldring MB, Yamada Y, Kaneko K, Arikawa-Hirasawa E, Ishijima M. Perlecan is required for the chondrogenic differentiation of synovial mesenchymal cells through regulation of Sox9 gene expression. *J Orthop Res* 2017;35:837-846. (IF:3.043)
  34. Liu L, Ishijima M, Kaneko H, Sadatsuki R, Hada S, Kinoshita M, Aoki T, Futami I, Yusup A, Arita H, Shiozawa J, Takazawa Y, Ikeda H, Kaneko K. The MRI-detected osteophyte score is a predictor of undergoing joint replacement in patients with end-stage knee osteoarthritis. *Mod Rheumatol* 2017;27:332-338. (IF:1.973)
- 【眼科】
35. Shijo T, Sakurada Y, Yoneyama S. Prevalence and characteristics of pseudodrusen subtypes in advanced age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2017;255:1125-1131. (IF:2.250)
- 【産科】
36. Shinohara S, Sunami R, Uchida Y, Hirata S, Suzuki K. Association between total dose of ritodrine hydrochloride and pulmonary oedema in twin pregnancy: a retrospective cohort study in Japan. *BMJ Open* 2017;7:e018118. (IF:2.376)
  37. Shinohara S, Uchida Y, Kasai M, Sunami R. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction. *Hypertens Pregnancy* 2017;36:269-275. (IF:1.736)
  38. Shinohara S, Kasai T, Kasai M, Hirata S. Delayed detection of ureteral thermal injury in laparoscopic surgery. *Gynecol Minim Invasive Ther* 2017;6:45.
  39. Shinohara S, Uchida Y, Kasai M, Ogawa T, Hirata S. Liver injury after cardiopulmonary resuscitation for cardiac arrest during cesarean delivery. *Int J Obstet Anesth* 2017;29:86-87. (IF:1.958)
- 【婦人科】
40. Morisada T, Teramoto K, Takano H, Sakamoto I, Nishio H, Iwata T, Hashi A, Katoh R, Okamoto A, Sasaki H, Nakatani E, Teramukai S, Aoki D. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women. *Cancer Epidemiol* 2017;50:60-67. (IF:2.619)
  41. Shinohara S, Sakamoto I, Numata M, Ikegami A, Teramoto K. Risk of spilling cancer cells during total laparoscopic hysterectomy in low-risk endometrial cancer. *Gynecol Minim Invasive Ther* 2017;6:113-115.
- 【新生児内科】
42. Kobayashi M, Yagasaki H, Saito T, Nemoto A, Naito A, Sugita K. Fetal goitrous hypothyroidism treated by intra-amniotic levothyroxine administration: case report and review of the literature. *J Pediatr Endocrinol Metab* 2017;30:1001-1005. (IF:1.239)
- 【小児科】
43. Saito T, Nakane T, Yagasaki H, Naito A, Sugita K. Shprintzen-Goldberg syndrome associated with first cervical vertebra defects. *Pediatr Int* 2017;59:1098-1100. (IF:0.939)
- 【小児循環器病センター】
44. Moriguchi T, Koizumi K, Matsuda K, Harii N, Goto J, Harada D, Sugawara H, Hoshiai M, Kise H, Baba A. Plasma exchange for the patients with dilated cardiomyopathy in children is safe and effective in improving both cardiac function and daily activities. *J Artif Organs* 2017;20:236-243. (IF:1.519)
- 【検査部】
45. Hara H, Misawa T, Ishii E, Nakagawa M, Koshiishi S, Amemiya K, Oyama T, Tominaga K, Cheng J, Tanaka A, Saku T. Differential diagnosis of well-differentiated squamous cell carcinoma from non-neoplastic oral mucosal lesions: New cytopathologic evaluation method dependent on keratinization-related parameters but not nuclear atypism. *Diagn Cytopathol* 2017;45:406-417. (IF:1.402)
- 【ゲノム解析センター】
46. Hirotsu Y, Ooka Y, Sakamoto I, Nakagomi H, Omata M. Simultaneous Detection of Genetic and Copy Number Alterations in BRCA1/2 Genes. *Oncotarget* 2017;8:114463-114473.
  47. Hirotsu Y, Nakagomi H, Amemiya K, Oyama T, Inoue M, Mochizuki H, Omata M. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient. *Med oncol* 2017;34:3. (IF:3.252)

## 【消化器内科】

1. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Al-Mahtab M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. *Hepatol Int* 2016;10:681-701. (IF:5.490)
2. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendation on treatment of hepatitis C. *Hepatol Int* 2016;10:702-726. (IF:5.490)
3. Younossi ZM, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. *Medicine (Baltimore)* 2016;95:e4243. (IF:1.870)
4. Masuzaki R, Karp SJ, Omata M. NAFLD as a risk factor for HCC: new rules of engagement? *Hepatol Int* 2016;10:533-534. (IF:5.490)
5. Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. *Ann Hepatol* 2016;15:333-349. (IF:1.895)
6. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH. Subramanian M, Kowdley K, Afdhal NH. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. *Hepatology* 2016;63:1112-1119. (IF:14.971)
7. Maruyama H, Shiha G, Yokosuka O, Kumar A, Sharma BC, Ibrahim A, Saraswat V, Lesmana CR, Omata M. Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography. *Hepatol Int* 2016;10:267-276. (IF:5.490)
8. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016;10:1-98. (IF:5.490)
9. Uchino K, Tateishi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Moriya K, Shiina S, Omata M, Koike K. Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. *Hepatol Res* 2016;46:259-268. (IF:3.440)
10. Yatsushashi H, Kodani N, Ugai H, Omata M. Open-label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment-naïve patients with chronic hepatitis C virus genotype 1 infection. *Hepatol Res* 2016;46:E189-E193. (IF:3.440)

## 【循環器内科】

11. Arumugam S, Sreedhar R, Thandavarayan RA, Karuppagounder V, Krishnamurthy P, Suzuki K, Nakamura M, Watanabe K. Angiotensin receptor blockers: Focus on cardiac and renal injury. *Trends Cardiovasc Med* 2016;26:221-228. (IF:4.462)

## 【外科】

12. Ikegame K, Takano A, Watanabe H, Yamamoto A, Miyasaka Y, Furuya K, Nakada H, Sugai H, Yasutome M, Inoue M, Hada M, Nakagomi H, Omata M, Oyama T. Biliary cancer developed after the reparative surgery for congenital choledochal cyst: a case report and review of the literature. *Int Cancer Conf J* 2016;6:43-49.
13. Takano A, Nakagomi H, Ikegame K, Yamamoto A, Watanabe H, Nakada H, Inoue M, Sugai H, Yasutome M, Furuya K, Hada M, Miyasaka Y, Oyama T, Omata M. Report of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence. *Int J Surg Case Rep* 2016;28:325-329.
14. Yamamoto A, Miyasaka Y, Furuya K, Watanabe H, Maruyama M, Nakada H, Takano A, Hada M, Nakagomi H, Omata M, Oyama T. Pseudo-Meigs' syndrome due to ovarian metastases from colon cancer: a case report and review of the literature. *Surg Case Rep* 2016;2:112.
15. Nakayama Y, Nakagomi H, Omori M, Inoue M, Takahashi K, Maruyama M, Takano A, Furuya K, Amemiya K, Ishii E, Oyama T. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer. *Breast Cancer* 2016;23:633-639. (IF:2.044)
16. Nakagomi H, Sakamoto I, Hirotsu Y, Amemiya K, Mochiduki H, Omata M. Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer. *Int J Clin Oncol* 2016;2:270-275. (IF:2.503)
17. Nakagomi H, Sakamoto I, Hirotsu Y, Amemiya K, Mochizuki H, Inoue M, Nakagomi S, Kubota T, Omata M. Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses. *Breast Cancer* 2016;23:649-653. (IF:2.044)
18. Shikata D, Nakagomi H, Takano A, Nakagomi T, Watanabe H, Maruyama M, Nakada H, Yamamoto A, Furuya K, Hada M, Miyasaka Y, Omata M, Oyama T. Report of a case with a spontaneous mesenteric hematoma that ruptured into the small intestine. *Int J Surg Case Rep* 2016;24:124-127.

## 【呼吸器外科】

19. Goto T, Hirotsu Y, Oyama T, Amemiya K, Omata M. Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients. *Med Oncol* 2016;33:29. (IF:3.252)

## 【整形外科】

20. Yuri M, Tabe Y, Tsuchiya K, Sadatsuki R, Aoki J, Horii T, Iba T, Ohsaka A. Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. *Clin Appl Thromb Hemost* 2016;22:453-458. (IF:1.846)
21. Koyama K, Sakuma M, Ohba T, Suzuki K, Haro H. Fractures lead to worsening of disease activity in rheumatoid arthritis. *Mod Rheumatol* 2016;26:873-877. (IF:1.973)

【産科】

22. Shinohara S, Uchida Y, Hirai M, Hirata S, Suzuki K. Relationship between maternal hypoglycaemia and small-for-gestational-age infants according to maternal weight status: a retrospective cohort study in two hospitals. *BMJ Open* 2016;6:e013749. (IF:2.376)

【婦人科】

23. Shinohara S, Sakamoto I, Numata M, Ikegami A, Teramoto K, Hirata S. Cardiac arrest during spinal anesthesia for cervical conization: a case report. *Clin Case Rep* 2016;4:466-468
24. Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, Amemiya K, Mochizuki H, Omata M. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. *Cancer* 2016;122:84-90. (IF:6.102)

【小児外科】

25. Emura T, Ohta H, Oyachi N, Suzuki T. A Modified Technique with a New Device of Laparoscopic Percutaneous Extraperitoneal Closure for Pediatric Inguinal Hernia. *J Laparoendosc Adv Surg Tech A* 2016;26:1028-1031. (IF:1.322)
26. Emura T, Hosoda K, Harai S, Oyachi N, Suzuki T. Dieulafoy lesion in a two-year-old boy: a case report. *J Med Case Rep* 2016;10:293.
27. Oyachi N, Yagasaki H, Suzuki T, Higashida K, Komai T, Hasuda N, Takano K, Obana K. Use of an appendicitis medical information sheet in the pediatric primary care system. *Pediatr Int* 2016;58:1032-1036. (IF:0.939)

【検査部】

28. Amemiya K, Hirotsu Y, Goto T, Nakagomi H, Mochizuki H, Oyama T, Omata M. Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors. *Cancer Medicine* 2016;5:3426-3436. (IF:3.357)

【ゲノム解析センター】

29. Hirotsu Y, Kojima Y, Okimoto K, Amemiya K, Mochizuki H, Omata M. Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer. *BMC Genomics* 2016;17:833. (IF:3.501)
30. Hirotsu Y, Zheng TH, Amemiya K, Mochizuki H, Guleng B, Omata M. Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. *Hepatol Res* 2016;46:1145-1151. (IF:3.440)

## 【消化器内科】

1. Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, Ibrahim A, Lau GK, Sharma BC, Hamid SS, Chuang WL, Dokmeci AK. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. *Hepatol Int* 2015;9:485-507. (IF:5.490)
2. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. *Hepatology* 2015;62:79-86. (IF:14.971)
3. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsunami H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. *Lancet Infect Dis* 2015;15:645-653. (IF:27.516)
4. Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan , Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour JF, Bourlière M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Kukulj G, Datsenko Y, Garcia M, Scherer J, Quinson AM, Stern JO, STARTVerso1 study group. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. *J Hepatol* 2015;62:1246-1255. (IF:18.946)
5. Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, Sato T, Nakagawa H, Masuzaki R, Asaoka Y, Kondo Y, Shiina S, Ikeda H, Omata M, Yoshida H, Koike K. Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. *Hepatol Res* 2015;45:415-422. (IF:3.440)
6. Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, Kumada H, Hayashi N, Koike K. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. *J Gastroenterol* 2015;50:350-360. (IF:5.130)
7. Kanda T, Yokosuka O, Omata M. Faldaprevir for the Treatment of Hepatitis C. *Int J Mol Sci* 2015;16:4985-4996. (IF:4.183)
8. Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabayashi K, Matsusaka K, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, Ikenoue T, Kurokawa M, Fukayama M, Kokudo N, Omata M, Koike K. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP alpha. *Carcinogenesis* 2014;35:2404-2414. (IF:4.004)

## 【循環器内科】

9. Arumugam S, Sreedhar R, Thandavarayan RA, Giridharan VV, Karuppagounder V, Pitchaimani V, Afrin MR, Miyashita S, Nomoto M, Harima M, Suzuki H, Nakamura T, Nakamura M, Suzuki K, Watanabe K. Telmisartan treatment targets inflammatory cytokines to suppress the pathogenesis of acute colitis induced by dextran sulphate sodium. *Cytokine* 2015;74:305-312. (IF:3.078)
10. Harima M, Arumugam S, Wen J, Pitchaimani V, Karuppagounder V, Afrin MR, Sreedhar R, Miyashita S, Nomoto M, Ueno K, Nakamura M, Watanabe K. Effect of carvedilol against myocardial injury due to ischemia-reperfusion of the brain in rats. *Exp Mol Pathol* 2015;98:558-562. (IF:2.350)
11. Karuppagounder V, Arumugam S, Thandavarayan RA, Pitchaimani V, Sreedhar R, Afrin R, Harima M, Suzuki H, Nomoto M, Miyashita S, Suzuki K, Nakamura M, Ueno K, Watanabe K. Tannic acid modulates NFkappaB signaling pathway and skin inflammation in NC/Nga mice through PPARgamma expression. *Cytokine* 2015;76:206-213. (IF:3.078)
12. Karuppagounder V, Arumugam S, Thandavarayan RA, Pitchaimani V, Sreedhar R, Afrin R, Harima M, Suzuki H, Nomoto M, Miyashita S, Suzuki K, Nakamura M, Watanabe K. Modulation of HMGB1 translocation and RAGE/NFkappaB cascade by quercetin treatment mitigates atopic dermatitis in NC/Nga transgenic mice. *Exp Dermatol* 2015;24:418-423. (IF:2.868)
13. Karuppagounder V, Arumugam S, Thandavarayan RA, Pitchaimani V, Sreedhar R, Afrin R, Harima M, Suzuki H, Suzuki K, Nakamura M, Ueno K, Watanabe K. Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation. *Int Immunopharmacol* 2015;28:154-159. (IF:3.361)
14. Sreedhar R, Arumugam S, Thandavarayan RA, Giridharan VV, Karuppagounder V, Pitchaimani V, Afrin R, Harima M, Nakamura T, Ueno K, Nakamura M, Suzuki K, Watanabe K. Toki-shakuyaku-san, a Japanese kampo medicine, reduces colon inflammation in a mouse model of acute colitis. *Int Immunopharmacol* 2015;29:869-875. (IF:3.361)
15. Watanabe K, Arumugam S, Sreedhar R, Thandavarayan RA, Nakamura T, Nakamura M, Harima M, Yoneyama H, Suzuki K. Small interfering RNA therapy against carbohydrate sulfotransferase 15 inhibits cardiac remodeling in rats with dilated cardiomyopathy. *Cell Signal* 2015;27:1517-1524. (IF:3.388)

## 【外科】

16. Maruyama M, Miyasaka Y, Takano A, Inoue M, Furuya K, Sugai H, Hada M, Nakagomi H. A case of advanced rectal cancer with rectovesical and ileal fistulae that developed hyperammonemic encephalopathy. *Surg Case Rep* 2015;1:88.
17. Takano A, Harai S, Nakagomi H, Maruyama M, Yamamoto A, Watanabe H, Nakada H, Furuya K, Hada M, Miyasaka Y, Oyama T, Omata M. Report of a case with T1a gallbladder poorly differentiated adenocarcinoma, solid type, which developed into lymph node metastases. *Surg Case Rep* 2015;1:116.
18. Takahashi K, Nakagomi H, Inoue M, Nakayama Y, Furuya K, Maruyama M, Takano A, Sugai H, Hada M, Miyasaka Y, Amemiya K, Oyama T. Life-threatening metastasis was suppressed by trastuzumab containing regimen in a patient with Her2-negative breast cancer. *Int Cancer Conf J* 2015;5:61-65.

19. Nakagomi H, Furuya K, Nakayama Y, Takahashi K, Maruyama M, Takano A, Sugai H, Hada M, Miyasaka Y, Saito A. A case of spontaneous intracranial hypotension caused by docetaxel treatment for metastatic breast cancer. *Int Cancer Conf J* 2015;4:184-187.  
【呼吸器外科】
20. Goto T, Hada M, Oyama T. Lung adenocarcinoma with clear cell features producing carbohydrate antigen 19-9. *Asian Cardiovasc Thorac Ann* 2015;23:985-987.  
【ゲノム解析センター】
21. Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Oyama T, Mochizuki H, Omata M. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. *Mol Genet Genomic Med* 2015;3:459-466. (IF:2.448)
22. Hirotsu Y, Kanda T, Matsumura H, Moriyama M, Yokosuka O, Omata M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. *Hepatol Int* 2015;9:424-430. (IF:5.490)
23. Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. *Mol Genet Genomic Med* 2015;3:121-129. (IF:2.448)



2014 年英文論文

【消化器内科】

1. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsunami H, Mizokami M. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. *J Viral Hepat* 2014;21:762-768. (IF:4.016)
2. Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabashi K, Matsusaka K, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, Ikenoue T, Kurokawa M, Fukayama M, Kokudo N, Omata M, Koike K. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP $\alpha$ . *Carcinogenesis* 2014;35:2404-2014. (IF:4.004)
3. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. *Hepatology* 2014;44:E137-E144. (IF:3.440)
4. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. *J Gastroenterol* 2014;49:748-754. (IF:5.130)
5. Yamada A, Watanabe H, Iwama T, Obi S, Omata M, Koike K. The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. *Fam Cancer* 2014;13:23-28. (IF:2.209)
6. Yu Y, Hou J, Omata M, Wang Y, Li L. Loss of HbsAg and antiviral treatment: from basics to clinical significance. *Hepatology* 2014;8:39-54. (IF:5.490)
7. Kanai F, Obi S, Fujiyama S, Shiina S, Tamai S, Mochizuki H, Koike Y, Imamura J, Yamaguchi T, Saida I, Yokosuka O, Omata M. An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma. *Hepatology* 2014;8:94-103. (IF:5.490)
8. Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, Tsuda Y, Steinmann G, Omata M. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. *Liver Int* 2014;34:78-88. (IF:5.542)

【緩和ケア科】

9. Maeda I, Tsuneto S, Miyashita M, Morita T, Umeda M, Motoyama M, Kosako F, Hama Y, Kizawa Y, Sasahara T, Eguchi K. Progressive Development and Enhancement of Palliative Care Services in Japan: Nationwide Surveys of Designated Cancer Care Hospitals for Three Consecutive Years. *J Pain Symptom Manage* 2014;48:364-373. (IF:3.378)

【心臓血管外科】

10. Kaku Y, Nakajima M, Ichihara Y, Iizuka K, Tsuchiya K. Modified Elephant Trunk Technique in Distal Anastomosis With the Aid of Antegrade Selective Cerebral Perfusion for Total Arch Replacement. *Ann Thorac Surg* 2014;97:1281-1285. (IF:3.919)

【小児科】

11. Tando T, Kaga Y, Ishii S, Aoyagi K, Sano F, Kanemura H, Sugita K, Aihara M. Developmental changes in frontal lobe function during a verbal fluency task: a multi-channel near-infrared spectroscopy study. *Brain Dev* 2014;36:844-52. (IF:1.756)
12. Sano F, Kanemura H, Tando T, Goto Y, Hosaka H, Sugita K, Aihara M. Depressive symptoms contribute to quality of life in children with epilepsy. *Eur J Paediatr Neurol* 2014;18:774-779. (IF:2.496)

【病理診断科】

13. Kawasaki T, Bussolati G, Marchiò C, Castellano I, Daniele L, Molinaro L, Hinata M, Furuya K, Nakagomi H, Oyama T, Tsunoda H, Sugai T, Katoh R, Sapino A. Well-differentiated neuroendocrine tumor of the breast showing peculiar endovascular spread. *Histopathology* 2014;64:597-600. (IF:3.294)

## 【消化器内科】

1. Kanda T, Yokosuka O, Omata M. Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients. *Chin Med J* 2013;126:4568-74. (IF:1.555)
2. Kanda T, Yokosuka O, Omata M. Androgen receptor and hepatocellular carcinoma. *J Gastroint Dig Syst* 2013;S12:012.
3. Kanda T, Yokosuka O, Omata M. Hepatitis B related chronic liver disease. Hepatitis B. Handbook of Gastroenterology, Marnum Al-Mahtab ed. Macmillan Medical Communications, Gurgaon, India. 2013 in press
4. K Nouse, K Miyahara, D Uchida, K Kuwaki, N Izumi, M Omata, T Ichida, M Kudo, Y Ku, N Kokudo, M Sakamoto, O Nakashima, T Takayama, Omatsui, Y Matsuyama, K Yamamoto, and the Liver Cancer Study Group of Japan. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer. *Br J Cancer* 2013;109:1904-1907. (IF:5.416)
5. Tanaka A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang YJ, Maeda S, Yoshida H, Omata M, Asahara H, Koike K. MicroRNA-140 acts as a liver tumor suppressor by controlling NF- $\kappa$ B activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. *Hepatology* 2013;75:162-170. (IF:14.971)
6. Urabe Y, Ochi H, Kato N, Kumar v, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, P.H.Y Lo, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, CHayama K, Nakamura Y, Matsuda K. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. *J Hepatol* 2013;58:875-882. (IF:18.946)
7. Tateishi R, Shiina S, Akanhane M, Sato J, Kondo Y, Masuzaki R, Nakagawa H, Asaoka Y, Goto T, Otomo K, Omata M, Yoshida H, Koike K. Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. *PLoS One* 2013;8:e59040. (IF:2.776)
8. Sasaki T, Isayama H, Nakai Y, Takahara N, Sasahira N, Kogure H, Mizuno S, Yagioka H, Ito Y, Yamamoto N, Hirano K, Toda N, Tada M, Omata M, Koike K. Improvement of prognosis for unresectable biliary tract cancer. *World J Gastroenterol* 2013;19:72-77. (IF:3.411)
9. Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, Koike K. CT With Hepatic Arteriography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial. *Am J Gastroenterol* 2013;108:1305-13. (IF:10.241)
10. Yamamoto S, Tateishi K, Kudo Y, Yamamoto K, Isagawa T, Nagae G, Nakatsuka T, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Aburatani H, Omata M, Koike K. Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. *Carcinogenesis* 2013;34:2380-2388. (IF:4.004)
11. Kanda T, Yokosuka O, Omata M. Chapter 2: Interferons in clinical trials. Emerging Therapeutic Options For Hepatitis C 2013:6-17
12. Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. *Clin Transl Med* 2013;2:9.
13. Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma. *Biology* 2013;2:304-316.
14. Hikita H, Nakagawa H, Tateishi R, Masuzaki R, Enooku K, Yoshida H, Omata M, Soroida Y, Sato M, Gotoh H, Suzuki A, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H. Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients. *J Gastroenterol* 2013;48:366-373. (IF:5.130)
15. Tanaka A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang J.Y, Maeda S, Yoshida H, Omata M, Asahara H, Koike K. MiRNA 40 acts as a liver tumor suppressor by controlling NF- $\kappa$ B activity via directly targeting Dnmt1 expression. *Hepatology* 2013;57:162-70. (IF:14.971)

## 【循環器内科】

16. Deyama J, Nakamura T, Takishima I, Fujioka D, Kawabata K, Obata JE, Watanabe K, Watanabe Y, Saito Y, Mishina H, Kugiyama K. Contrast-enhanced ultrasound imaging of carotid plaque neovascularization is useful for identifying high-risk patients with coronary artery disease. *Circ J* 2013;77:1499-1507. (IF:3.025)

## 【呼吸器内科】

17. Okamoto T, Miyazaki Y, Ogura T, Chida K, Kohno N, Kohno S, Taniguchi H, Akagawa S, Mochizuki Y, Yamauchi K, Takahashi H, Johkoh T, Homma S, Kishi K, Ikushima S, Konno S, Mishima M, Ohta K, Nishioka Y, Yoshimura N, Munakata M, Watanabe K, Miyashita Y, Inase N. A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. *Respir Investig* 2013;5:191-199.

## 【リウマチ・膠原病内科】

18. Kanzaki T, Kawahata K, Kanda H, Fujio K, Kubo K, Akahira L, Michishita K, Eri T, Yamamoto K. Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis. *Rheumatol Int* 2013;33:871-877. (IF:2.200)
19. Nagafuchi Y, Sumitomo S, Soroida Y, Kanzaki T, Iwasaki Y, Michishita K, Iwai T, Ikeda H, Fujio K, Yamamoto K. The power Doppler twinkling artefact associated with periarticular calcification induced by intra-articular corticosteroid injection in patients with rheumatoid arthritis. *Ann Rheum Dis* 2013;72:1267-1269. (IF:14.299)

## 【化学療法科】

20. Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan. *J Infect Chemother* 2013;19:1126-1134. (IF:1.539)

## 【皮膚科】

21. Oiso N, Suzuki T, Wataya-Kaneda M, Tanemura A, Tanioka M, Fujimoto T, Fukai K, Kawakami T, Tsukamoto K, Yamaguchi Y, Sano S, Mitsuhashi Y, Nishigori C, Morita A, Nakagawa H, Mizoguchi M, Katayama I. Guidelines for the diagnosis and treatment of vitiligo in Japan. *J Dermatol* 2013;40:344-354. (IF:3.377)

## 【泌尿器科】

22. Suzuki T, Hiragata S, Hosaka K, Oyama T, Kuroda N, Hes O, Michal M. Malignant mixed epithelial and stromal tumor

of the kidney:Report of the first male case. *Int J Urol* 2013;20:448-450. (IF:2.107)

【小児外科】

23. Oyachi N, Obana K, Suzuki T, Ochiai T, Mochizuki H. Preoperative endoscopic extraction of a huge pancreatic protein plug in a choledochal cyst: A case report. *J Ped Surg Case Reports* 2013;1:364-367.
24. Oyachi N, Obana K, Suzuki T, Kimura S, Chino K, Oyama T, Takano K. Costal BCG osteomyelitis developing 1 year after BCG vaccination. *Pediatr Int* 2013;55:641-643. (IF:0.939)

## 【消化器内科】

1. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. *Invest New Drugs* 2012;30:708-713. (IF:2.663)
2. Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, Koike K. Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. *J Gastroenterol* 2012;47:71-78. (IF:5.130)
3. Kajiwara H, Yamaji Y, Sugimoto T, Yamada A, Watabe H, Yoshida H, Omata M, Koike K. Withdrawal times affects polyp and diverticulum detection on the right-side colon. *Hepatogastroenterology* 2012;59:108-111.
4. Sugimoto T, Okamoto M, Mitsuno Y, Kondo S, Ogura K, Ohmae T, Mizuno H, Yoshida S, Isomura Y, Yamaji Y, Kawabe T, Omata M, Koike K. Endoscopic Submucosal dissection is an effective and safe therapy for early gastric neoplasms: a multicenter feasible study. *J Clin Gastroenterol* 2012;46:124-129. (IF:2.724)
5. Kawakubo K, Isayama H, Nakai Y, Togawa O, Sasahira N, Kogure H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Risk factors for pancreatitis following transpapillary self-expandable metal stent placement. *Surg Endosc* 2012;26:771-776. (IF:3.209)
6. Tateishi R, Omata M. Hepatocellular carcinoma in 2011: Genomics in hepatocellular carcinoma-a big step forward. *Nat Rev Gastroenterol Hepatol* 2012;9:69-70. (IF:23.570)
7. Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, Ohta M, Tada M, Tanaka Y, Ikenoue T, Tateishi K, Isayama H, Kanai F, Fukushima N, Tada M, Kawabe T, Omata M, Koike K. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. *J Gastroenterol* 2012;47:201-213. (IF:5.130)
8. Yashima Y, Sasahira N, Isayama H, Kogure H, Ikeda H, Hirano K, Mizuno S, Yagioka H, Kawakubo K, Sasaki T, Nakai Y, Tada M, Yoshida H, Omata M, Koike K. Acoustic radiation force impulse elastography for noninvasive assessment of chronic pancreatitis. *J Gastroenterol* 2012; 47:427-432. (IF:5.130)
9. Takahara N, Isayama H, Sasaki T, Tsujino T, Toda N, Sasahira N, Mizuno S, Kawakubo K, Kogure H, Yamamoto N, Nakai Y, Hirano K, Tada M, Omata M, Koike K. Endoscopic papillary balloon dilation for bile duct stones in patients on hemodialysis. *J Gastroenterol* 2012;47:918-923. (IF:5.130)
10. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. *Am J Gastroenterol* 2012;107:569-577. (IF:10.241)
11. Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, Koike K. Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial. *Hepatol Int* 2012;6:639-645. (IF:5.490)
12. Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. *J Gastroenterol* 2012; 2012:477-485. (IF:5.130)
13. Isayama H, Sasaki T, Nakai Y, Togawa O, Kogure H, Sasahira N, Yashima Y, Kawakubo K, Ito Y, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Management of malignant gastric outlet obstruction with a modified triple-layer covered metal stent. *Gastrointest Endosc* 2012;75:757-763. (IF:7.229)
14. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. *Hepatol Int* 2012;6:409-435. (IF:5.490)
15. Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. *World J Gastroenterol* 2012; 28:1385-1390. (IF:3.411)
16. Y.-F. Liaw, J.-H. Kao, T Piratvisuth, H. L.Y. Chan, R.-N. Chien, C.-J. Liu, E Gane, S Locarnini, S.-G. Lim, K.-H. Han, D Amarapurkar, G Cooksley, W Jafari, R Mohamed, J.-L. Hou, W.-L. Chuang, L.A. Lesmana, J.D. Sollano, D.-J. Suh, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Heptol Int* 2012;6:531-561. (IF:5.490)
17. Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, Koike K. Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial. *Hepatol Int* 2012;6:639-645. (IF:5.490)
18. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. *Br J Cancer* 2012;106:1934-1939. (IF:5.416)
19. Matsubara S, Tada M, Akahane M, Yagioka H, Kogure H, Sasaki T, Arizumi T, Togawa O, Nakai Y, Sasahira N, Hirano K, Tsujino T, Isayama H, Toda N, Kawabe T, Ohtomo K, Omata M. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. *Pancreas* 2012;41:1241-1246. (IF:2.675)
20. Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, Mizuno S, Yashima Y, Ito Y, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving self-expandable metallic stents for palliation. *Dig Endosc* 2012;24:226-230. (IF:3.640)
21. Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H, Omata M, Koike K. Percutaneous ethanol injection for hepatocellular carcinoma:20-year outcome and prognostic factors. *Liver int*

- 2012;32:1434-1442. (IF:5.542)
22. Kambe H, Yamaji Y, Sugimoto T, Yamada A, Watabe H, Yoshida H, Omata M, Koike K. A randomized controlled trial of sodium phosphate tablets and polyethylene glycol solution for polyp detection. *J Dig Dis* 2012;13:374-380. (IF:1.689)
  23. Masuzaki R, Seth J Karp, Omata M. New serum markers of hepatocellular carcinoma. *Semin Oncol* 2012;39:434-439. (IF:3.606)
  24. Kanda T, Imazeki F, Kanai F, Toda M, Yokosuka O, Omata M. Signaling pathways involved in molecular carcinogenesis of hepatocellular carcinoma. In: Qiao L, eds. *Molecular Aspects of Hepatocellular Carcinoma* 2012;39-55.
  25. Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. *ScientificWorldJournal* 2012;2012:496453.
  26. Yoshida S, Watabe H, Isyama H, Kogure H, Nakai Y, Yamamoto N, Sasaki T, Kawakubo K, Hamada T, Ito Y, Yashima Y, Sasahira N, Hirano K, Yamaji Y, Tada M, Omata M, Koike K. Feasibility of a new self-expandable metallic stent for patients with malignant colorectal obstruction. *Dig Endosc* 2013;25:160-166. (IF:3.640)
  27. Isayama H, Mukai T, Itoi T, Maetani I, Nakai Y, Kawakami H, Yasuda I, Maguchi H, Ryozaawa S, Hanada K, Hasebe O, Ito K, Kawamoto H, Mochizuki H, Igarashi Y, Irisawa A, Sasaki T, Togawa O, Hara T, Kamada H, Toda N, Kogure H. Comparison of partially covered nitinol stents with partially covered stainless stents as a historical control in a multicenter study of distal malignant biliary obstruction:the WATCH study. *Gastrointest Endosc* 2012;76:84-92. (IF:7.229)
- 【循環器内科】
28. Yoshizaki T, Umetani K, Ino Y, Takahashi S, Nakamura M, Seto T, Aizawa K. Activated inflammation is related to the incidence of atrial fibrillation in patients with acute myocardial infarction. *Intern Med* 2012;51:1467-1471. (IF:0.956)
- 【呼吸器内科】
29. Honda T, Kobayashi H, Saiki M, Sogami Y, Miyashita Y, Inase N. Gastroesophageal variceal hemorrhage induced by metastatic liver tumor of lung cancer. *Case Rep Oncol* 2012;5:644-650.
- 【化学療法科】
30. Iino M. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide. *Int J Hematol* 2012;95:223-224. (IF:2.251)
- 【外科】
31. Furuya K, Hada M, Sugai H, Miyasaka Y, Nakagomi H, Oyama T, Mitsui T. Gastrointestinal stromal tumor arising in an ileal duplication: report of a case. *Surg Today* 2012;42:1234-1239. (IF:2.077)
- 【検査部】
32. Hara H, Ishii E, Hondo T, Nakagawa M, Teramoto K, Oyama T. Cytological features of atypical carcinoid combined with adenocarcinoma of the uterine cervix. *Diagn Cytopathol* 2012;40:724-728. (IF: 1.402)

## 【消化器内科】

1. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Kogure H, Yagioka H, Yashima Y, Togawa O, Arizumi T, Matsubara S, Hirano K, Tada M, Omata M, Koike K. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer. *Crit Rev Oncol Hematol* 2011;78:252-259. (IF:5.012)
2. Kogure H, Isayama H, Nakai Y, Tsujino T, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Kawakubo K, Sasaki T, Hirano K, Sasahira N, Tada M, Omata M, Koike K. Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study. *Surg Endosc* 2011;25:463-467. (IF:3.209)
3. Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K. Utility of contrast enhanced ultrasonography with sonazoid in radiofrequency ablation for hepatocellular carcinoma. *J Gastroenterol Hepatol* 2011;26:759-764. (IF:3.632)
4. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. *Invest New Drugs* 2011;10:9553-9559. (IF:2.663)
5. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. *Invest New Drugs* 2011;10:9485-9494. (IF:2.663)
6. Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. *Cancer Chemother Pharmacol* 2011;67:847-853. (IF:3.008)
7. Seto M, Ohta M, Ikenoue T, Sugimoto T, Asaoka Y, Tada M, Mohri D, Kudo Y, Ijichi H, Tateishi K, Otsuka M, Hirata Y, Maeda S, Koike K, Omata M. Reduced expression of RAS protein activator like-1 in gastric cancer. *Int J Cancer* 2010;128:1293-1302. (IF:4.982)
8. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, Kondo Y, Taniguchi M, Tagawa K, Ikeda M, Morizane C, Okusaka T, Arioka H, Shiina S, Omata M. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. *Cancer Chemother Pharmacol* 2011;67:315-324. (IF:3.008)
9. Yashima Y, Tsujino T, Masuzaki R, Nakai Y, Hirano K, Tateishi R, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M. Increased liver elasticity in patients with biliary obstruction. *J Gastroenterol* 2011;46:86-91. (IF:5.130)
10. Kondo Y, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Masuzaki R, Asaoka Y, Fujie H, Goto T, Omata M, Yoshida H, Koike K. Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis. *Liver Int* 2011;31:197-205. (IF:5.542)
11. Eguchi S, Kanematsu T, Arai S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. *Br J Surg* 2011;98:552-557. (IF:5.586)
12. Masuzaki R, Omata M. Screening Program in High-Risk Populations. *Hepatocellular Carcinoma* 2011:55-68.
13. Omata M. Radiofrequency Ablation, the answer for therapy of HCC lesions of < 2cm. *Hepatology Digest the 21st APASL 2011 Bangkok*. 2011;3:18.
14. Nakagawa H, Hirata Y, Takeda K, Hayakawa Y, Sato T, Kinoshita H, Sakamoto K, Nakata W, Hikiba Y, Omata M, Yoshida H, Koike K, Ichiji H, Maeda S. Apoptosis signal-regulating Kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated mitogen-activated protein Kinase. *Hepatology* 2011;54:185-195. (IF:14.971)
15. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuji K, Toyota J, Seki T, Osa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Kokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omtata M. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. *Hepatology* 2011;54:532-540. (IF:14.971)
16. Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, Koike K, Omata M. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. *Hepatol Int* 2011;5:767-773. (IF:5.490)
17. Takata A, Otsuka M, Kogiso T, Kojima K, Yoshikawa T, Tateishi R, Kato N, Shiina S, Yoshida H, Omata M, Koike K. Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines. *Hepatol Int* 2011;5:890-898. (IF:5.490)
18. Yashima Y, isayama H, Tsujino T, Nagano R, Yamamoto K, Mizuno S, Yagioka H, Kawakubo K, Sasaki T, Kogure H, Nakai Y, Hirano K, Sasahira N, Tada M, Kawabe T, Koike K, Omata M. A large volume of visceral adipose tissue leads to severe acute pancreatitis. *J Gastroenterol* 2011;46:1213-1218 (IF:5.130)
19. Kogure H, Tsujino T, Yamamoto K, Mizuno S, Yashima Y, Yagioka H, Kawakubo K, Sasaki T, Nakai Y, Sasahira N, Isayama H, Tada M, Kawabe T, Omata M, Harada S, Ota Y, Koke K. Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. *J Gastroenterol* 2011;46:1411-7 (IF:5.130)
20. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, Koike K. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. *Int J Cancer* 2011;129:2226-2235. (IF:4.982)
21. Fujiwara K, Kojima H, Yasui S, Okitsu K, Yonemitsu Y, Omata M, Yokosuka O. Hepatitis A viral load in relation to severity of the infection. *J Med Virol* 2011;83:201-207. (IF:2.049)
22. Hayakawa Y, Hirata Y, Nakagawa H, Sakamoto K, Hikiba Y, Kinoshita H, Nakata W, Takahashi R, Tateishi K, Tada M, Akanuma M, Yoshida H, Takeda K, Ichijo H, Omata M, Maeda S, Koike K. Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. *Proc Natl Acad Sci U S A*.

- 2011;108:780-785. (IF:9.580)
23. Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K, Yatomi Y. Autotaxin as a novel serum marker of liver fibrosis. *Clin Chim Acta* 2011;412:1201-1206. (IF:2.735)
  24. Nakai Y, Ikeda H, Nakamura K, Kume Y, Fujishiro M, Sasahira N, Hirano K, Isayama H, Tada M, Kawabe T, Komatsu Y, Omata M, Aoki J, Koike K, Yatomi Y. Specific increase in serum autotaxin activity in patients with pancreatic cancer. *Clin Biochem* 2011;44:576-581. (IF:2.430)
  25. Nakai Y, Isayama H, Kawakubo K, Kogure H, Sasaki T, Togawa O, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Endoscopic removal of a biliary covered metallic stent with the invagination method. *Endoscopy* 2011;43:E30-E31. (IF:6.381)
  26. Nakai Y, Isayama H, Togawa O, Kogure H, Tsujino T, Yagioka H, Yashima Y, Sasaki T, Ito Y, Matsubara S, Hirano K, Sasahira N, Toda N, Tada M, Kawabe T, Omata M, Koike K. New method of covered wallstents for distal malignant biliary obstruction to reduce early stent-related complications based on characteristics. *Dig Endosc* 2011;23:49-55. (IF:3.640)
  27. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. *Invest New Drug* 2011;29:1488-1493. (IF:2.663)
  28. Takano N, Yamada A, Watabe H, Togo G, Yamaji Y, Yoshida H, Kawabe T, Omata M, Koike K. Single-balloon versus double-balloon endoscopy for achieving total enteroscopy: a randomized, controlled trial. *Gastrointest Endosc* 2011;73:734-739. (IF:7.229)
  29. Yamada A, Watabe H, Obi S, Sugimoto T, Kondo S, Ohta M, Togo G, Ogura K, Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Koike K, Omata M. Surveillance of small intestinal abnormalities in patients with hepatocellular carcinoma: a prospective capsule endoscopy study. *Dig Endosc* 2011;23:124-129. (IF:3.640)
  30. Kawakubo K, Isayama H, Nakai Y, Togawa O, Sasahira N, Kogure H, Sasaki T, Matsubara S, Yamamoto N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Efficacy and safety of covered self-expandable metal stents for management of distal malignant biliary obstruction due to lymph node metastases. *Surg Endosc* 2011; 25:3094-100. (IF:3.209)
  31. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 2011;43:455-458. (IF:25.455)
  32. Sakitani K, Hirata Y, Watabe H, Yamada A, Sugimoto T, Yamaji Y, Yoshida H, Maeda S, Omata M, Koike K. Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration. *J Gastroen Hepatol* 2011;26:1570-1575. (IF:3.632)
  33. Tada M, Nakai Y, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Omata M, Koike K. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. *World J Clin Oncol* 2011;2:158-163. (IF:2.290)
  34. Nakai Y, Isayama H, Tsujino T, Sasahira N, Hirano K, Kogure H, Sasaki T, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Yamamoto N, Tada M, Omata M, Koike K. Impact of introduction of wire-guided cannulation in therapeutic biliary ERCP. *J Gastroen Hepatol* 2011;26:1552-1558. (IF:3.632)
  35. Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K. MicroRNA122 is a key regulator of  $\alpha$ -fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. *Nat Commun* 2011;2:338. (IF:11.878)
  36. Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. *Oncology* 2011;80:97-101. (IF:2.278)
  37. Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, Kanai F, Omata M, Koike K. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. *J Hepatol* 2011;55:1400-1408. (IF:18.946)
  38. Hamada T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, Tsujino T, Sasahira N, Hirano K, Yamamoto N, Arizumi T, Ito Y, Matsubara S, Sasaki T, Yagioka H, Yashima Y, Mohri D, Miyabayashi K, Mizuno S, Nagano R, Takahara N, Toda N, Tada M, Omata M, Koike K. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. *Gastrointest Endosc* 2011; 74:548-555. (IF:7.229)
  39. Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. *J Clin Invest* 2011;121:14106-1417. (IF:12.282)
  40. Otsuka M, Takata A, Yoshikawa T, Kojima K, Kishikawa T, Shibata C, Takekawa M, Yoshida H, Omata M, Koike K. Receptor for activated protein kinase C: requirement for efficient microRNA function and reduced expression in hepatocellular carcinoma. *PLoS One* 2011;6:e24359. (IF:2.776)
  41. Yamada A, Watabe H, Yamaji Y, Yoshida H, Omata M, Koike K. Incidence of small intestinal lesions in patients with iron deficiency anemia. *Hepatogastroenterology* 2011;58:1240-1243.
- 【呼吸器内科】
42. Honda T, Tsuzaki Y, Mitaka K, Fukasawa K, Miyashita Y, Marino K, Saito A, Oyama T, Inase N. Tracheoesophageal fistula closed by chemoradiotherapy in lung cancer. *Case Rep Oncol* 2011;4:350-357.
- 【精神科】

43. Sekimoto M, Kato M, Watanabe T, Kajimura N, Takahashi K. Cortical regional differences of delta waves during all-night sleep in schizophrenia. *Schizophr Res* 2011;126:284-290. (IF:4.569)
- 【心臓血管外科】
44. Nakajima M, Tsuchiya K, Ichihara Y, Amenomori S, Koshiyama H, Kaku Y. Forty-year durability of a Smeloff-Cutter ball valve prosthesis in the mitral position. *Gen Thorac Cardiovasc Surg* 2011;59:809-811. (IF:1.129)
45. Koshiyama H, Nakajima M, Amenomori S, Tsuchiya K. A refined flanged Bentall technique using Valsalva tube graft for proximal reinforcement. *Eur J Cardiothorac Surg* 2011;40:1537-1539. (IF:3.847)
- 【口腔外科】
46. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K, Inazawa J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. *Cancer Res* 2011;71:5765-5778. (IF:8.378)
- 【眼科】
47. Tanabe N, Go K, Sakurada Y, Imasawa M, Mabuchi F, Chiba T, Abe K, Kashiwagi K. A remote operating slit lamp microscope system. Development and its utility in ophthalmologic examinations. *Methods Inf Med* 2011;50:427-434. (IF:1.024)
- 【小児外科】
48. Oyachi N, Obana K, Kimura S, Kubo M, Naito A, Nemoto A. Use of a flexible Blake silicone drains for peritoneal dialysis in the neonatal intensive care unit. *Pediatr Int* 2011;53:417-418. (IF:0.939)
49. Kubo M, Iwashita K, Oyachi N, Oyama T, Yamamoto T. Two different types of infantile renal cell carcinomas associated with tuberous sclerosis. *J Pediatr Surg* 2011;46:E37-E41. (IF:2.092)
- 【病理診断科】
50. Kawasaki T, Oyama T, Nakagomi H, Furuya K, Kondo T, Nakazawa T, Mochizuki K, Yamane T, Miyazawa T, Ishii Y, Fukushima K, Moriya T, Tsunoda H, Katoh R. Massive myoepithelial proliferation (myoepitheliosis) with lumpy deposits of basement membrane material closely associated with apocrine adenosis and ductal carcinoma in situ of the breast. *Pathol Int* 2011;61:615-617. (IF:5.490)



## 【消化器内科】

1. Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, Yamamoto K, Yamamoto S, Kudo Y, Mohri D, Isomura Y, Ijichi H, Tateishi K, Kanai F, Ogawa S, Omata M, Koike K. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. *Biochem Biophys Res Commun* 2010;394:1042-1046. (IF:2.705)
2. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. *Br J Cancer* 2010;103:1644-1648. (IF:5.416)
3. Tada M, Kanai F, Tanaka Y, Sanada M, Nannya Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Imazeki F, Yoshida H, Ogawa S, Yokosuka O, and Omata M. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. *Cancer Sci* 2010;101:1261-1269. (IF:4.751)
4. Nishi H, Shibagaki Y, Hirano K, Akahane M, Kido R, Nangaku M, Kaname S, Sasahira N, Isayama H, Tada M, Tsukamoto R, Ohtomo K, Omata M, Fujita T. Laboratory and imaging features of kidney involvement in autoimmune pancreatitis: incidence, correlation, and steroid therapy response. *Clin Nephrol* 2010;73:253-259. (IF:1.079)
5. Masuzaki R, Yoshida H, Omata M. Does chemotherapy prevent HCV-related hepatocellular carcinoma? *Dig Liver Dis* 2010;42:S281-S286. (IF:3.037)
6. Tsujino T, Yamada A, Isayama H, Kogure H, Sasahira N, Hirano K, Tada M, Kawabe T, Omata M. Experiences of biliary interventions using short double-balloon enteroscopy in patients with Roux-en-Y anastomosis or hepaticojejunostomy. *Dig Endosc* 2010;22:211-216. (IF:3.640)
7. Tsujino T, Sasahira N, Hirano K, Tateishi R, Isayama H, Tada M, Shiina S, Yoshida H, Kawabe T, Omata M. Endoscopic management of biliocutaneous fistula after percutaneous radiofrequency ablation therapy for hepatocellular carcinoma. *Dig Endosc* 2010;22:53-55. (IF:3.640)
8. Goto O, Fujishiro M, Kodashima S, Ono S, Niimi K, Yamamichi N, Omata M. Feasibility of endoscopic submucosal dissection for patients with chronic renal failure on hemodialysis. *Dig Endosc* 2010;22:45-48. (IF:3.640)
9. Imazeki F, Yokosuka O, Omata M. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study. *Expert Rev Anti Infect Ther* 2010;8:497-499. (IF:3.090)
10. Sakamoto K, Hikiba Y, Nakagawa H, Hayakawa Y, Yanai A, Akanuma M, Ogura K, Hirata Y, Kaestner KH, Omata M, Maeda S. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. *Gastroenterology* 2010;139:226-38.e6. (IF:19.233)
11. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, Han J. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. *Gastroenterology* 2010;138:1255-1265, 1265.e1-9. (IF:19.233)
12. Hayakawa Y, Hirata Y, Nakagawa H, Sakamoto K, Hikiba Y, Otsuka M, Ijichi H, Ikenoue T, Tateishi K, Akanuma M, Ogura K, Yoshida H, Ichijo H, Omata M, Maeda S. Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses. *Gastroenterology* 2010;138:1055-1067.e1-4. (IF:19.233)
13. Hirano K, Tada M, Isayama H, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Sasaki T, Kogure H, Togawa O, Arizumi T, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Kawabe T, Omata M. Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. *Gastrointest Endosc* 2010;71:85-90. (IF:7.229)
14. Masuzaki R, Yoshida H, Kato N and Omata M Hepatitis C and Hepatocellular Carcinoma Hepatocellular Carcinoma
15. Ahn SH, Chan HLY, Chen P-J, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF, APPROACH Working Group. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. *Hepatol Int* 2010;4:386-395. (IF:5.490)
16. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RTP, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafari W, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int* 2010;4:439-474. (IF:5.490)
17. Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, Yatsushashi H, Hayashi N, Ishikawa H, Seriu T, Omata M. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. *Hepatol Int* 2010;4:594-600. (IF:5.490)
18. Yoshida S, Watabe H, Akahane M, Kyoden Y, Ishikawa H, Yamada A, Sugimoto T, Ohata M, Ogura K, Yamaji Y, Ohtomo K, Kokudo N, Koike K, Omata M. Usefulness of multi-detector helical CT with multiplanar reconstruction for depicting the duodenal varices with multiple collateral shunt vessels. *Hepatol Int* 2010;4:775-778. (IF:5.490)
19. Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. *Hepatol Int* 2010;4:414-422. (IF:5.490)
20. Ikai I, Kudo M, Arai S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y, Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan. *Hepatol Res* 2010;40:1043-1059. (IF:3.440)
21. Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J, Matsui Y, Togashi J, Akahane M, Makuuchi M, Omata M, Kokudo N. Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. *Hepatol Res* 2016;40:278-286. (IF:3.440)
22. Sugimoto T, Ohta M, Ikenoue T, Yamada A, Tada M, Fujishiro M, Ogura K, Yamaji Y, Okamoto M, Kanai F, Kawabe T, Omata M. Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations. *Int J Cancer* 2010;127:1562-1569. (IF:4.982)
23. Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H, Katoh S, Suzuki A, Koike Y, Yatomi Y, Omata M, Koike K. Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. *J Gastroenterol* 2010;45:876-884. (IF:3.632)

24. Tsujino T, Yoshida H, Isayama H, Ito Y, Yashima Y, Yagioka H, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Hirano K, Tada M, Kawabe T, Omata M, Koike K. Endoscopic papillary balloon dilation for bile duct stone removal in patients 60 years old or younger. *J Gastroenterol* 2010;45:1072-1079. (IF:3.632)
25. Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K. Bezafibrate for the treatment of primary sclerosing cholangitis. *J Gastroenterol* 2010;45:758-762. (IF:3.632)
26. Isomura Y, Yamaji Y, Ohta M, Seto M, Asaoka Y, Tanaka Y, Sasaki T, Nakai Y, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M, Koike K. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. *J Gastroenterol* 2010;45:1045-1052. (IF:3.632)
27. Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Omata M, Koike K. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. *Jpn J Clin Oncol* 2010;40:774-780. (IF:2.183)
28. Goto E, Tateishi R, Shiina S, Masuzaki R, Enooku K, Sato T, Ohki T, Kondo Y, Goto T, Yoshida H, Omata M. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. *J Clin Gastroenterol* 2010;44:374-380. (IF:2.724)
29. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A; World Gastroenterology Organization. Hepatocellular carcinoma (HCC): a global perspective. *J Clin Gastroenterol* 2010;44:239-245. (IF:2.724)
30. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid S, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. *J Gastrointest Liver Dis* 2010;19:311-317. (IF:2.063)
31. Masuzaki R, Yoshida H, Tateishi R, Omata M. Staging systems: is there a surgical staging and a medical one?: hepatologist's perspective. *J Hepatobiliary Pancreat Sci* 2010;17:440-442. (IF:2.353)
32. Yokosuka O, Takaguchi K, Fujioka K, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T and Omata M. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. *J Hepatol* 2010;52:791-799. (IF:18.946)
33. Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M. Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. *J Viral Hepat* 2010;17:91-97. (IF:4.016)
34. Chang JH, Kato N, Muroyama R, Taniguchi H, Guleng B, Dharel N, Shao RX, Tateishi K, Jazag A, Kawabe T, Omata M. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment. *Liver Int* 2010;30:311-318. (IF:5.542)
35. Masuzaki R, Yoshida H, Omata M. Interferon Reduces the Risk of Hepatocellular Carcinoma in Hepatitis C Virus-Related Chronic Hepatitis / Liver Cirrhosis. *Oncology* 2010;78:17-23. (IF:2.278)
36. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M, Koike K. Impact of S-1 on the survival of patients with advanced pancreatic cancer. *Pancreas* 2010;39:989-993. (IF:2.675)
37. Isayama H, Kawabe T, Nakai Y, Ito Y, Togawa O, Kogure H, Yashima Y, Yagioka H, Matsubara S, Sasaki T, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M. Management of distal malignant biliary obstruction with the ComVi stent, a new covered metallic stent. *Surg Endosc* 2010;24:131-137. (IF:3.209)
38. Asaoka Y, Kanai F, Ichimura T, Tateishi K, Tanaka Y, Ohta M, Seto M, Tada M, Ijichi H, Ikenoue T, Kawabe T, Isobe T, Yaffe MB, Omata M. Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3. *J Biol Chem* 2010;285:4185-4194. (IF:4.106)
- 【心臓血管外科】
39. Nakajima M, Tsuchiya K, Honda Y, Koshiyama H. Midterm outcome of leaflet folding plasty for mitral regurgitation due to posterior leaflet prolapse. *Gen Thorac Cardiovasc Surg* 2010;58:271-275. (IF:1.219)
- 【眼科】
40. Sekine A, Imasawa M, Iijima H. Retinal thickness and perimetric sensitivity in central serous chorioretinopathy. *Jpn J Ophthalmol* 2010;54:578-583. (IF: 1.653)
- 【母性科】
41. Sunami R, Komuro M, Tagaya H, Hirata S. Migration of microchimeric fetal cells into maternal circulation before placenta formation. *Chimerism* 2010;1:66-68.
42. Sunami R, Komuro M, Yuminamochi T, Hoshi K, Hirata S. Fetal cell microchimerism develops through the migration of fetus-derived cells to the maternal organs early after implantation. *J Reprod Immunol* 2010;84:117-123. (IF:3.091)
- 【小児科】
43. Yagasaki H, Kobayashi K, Saitou T, Nagamine K, Mitsui Y, Mochizuki M, Kobayashi K, Cho H, Ohyama K, Aramiya S, Nakazawa S. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens. *Exp Clin Endocrinol Diabetes* 2010;118:195-199. (IF:1.927)
44. Yagasaki H, Kobayashi K, Nemoto A, Naito A, Sugita K, Ohyama K. Late-onset circulatory dysfunction after thyroid hormone treatment in an extremely low birth weight infant: a case report. *J Pediatr Endo and Metab* 2010;23:153-158. (IF: 1.239)
- 【救急科】
45. Tagami T, Kushimoto S, Yamamoto Y, Atsumi T, Tosa R, Matsuda K, Oyama R, Kawaguchi T, Masuno T, Hiramata H, Yokota H. Validation of extravascular lung water measurement by single transpulmonary thermodilution: human autopsy study. *Crit Care* 2010;14:R162. (IF:6.959)
- 【放射線診断科】

46. Kato S, Nambu A, Onishi H, Saito A, Kuriyama K, Komiyama T, Marino K, Araki T. Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma. *Jpn J Radiol* 2010;28:259-265. (IF:1.500)
47. Sawada E, Nambu A, Motosugi U, Araki T, Kato S, Sato Y, Saito A, Ishihara H, Okuwaki H, Ozawa K, Nishikawa K, Miyazawa M, Miyata K. Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings. *Jpn J Radiol* 2010;28:251-258. (IF:1.500)
48. Motosugi U, Ichikawa T, Sano K, Sou H, Muhi A, Koshiishi T, Ehman RL, Araki T. Magnetic resonance elastography of the liver: preliminary results and estimation of inter-rater reliability. *Jpn J Radiol* 2010;28:623-627. (IF:1.500)
49. Nambu A, Kato S, Motosugi U, Araki T, Okuwaki H, Nishikawa K, Saito A, Matsumoto K, Ichikawa T. Thin-section CT of mediastinum in preoperative N-staging of non-small cell lung cancer. *Eur J Radiol* 2010;73:510-517. (IF:2.948)

県立中央病院医師の専門性資格

専門医種類		人数	医師名
基本領域	1 整形外科専門医	6	千野・岩瀬弘・佐久間・定月・小畑・笹本
	2 皮膚科専門医	2	塚本・長田
	3 麻酔科専門医	4	久米・正宗・近藤・阿部文
	4 放射線科専門医	3	遠山・斎藤・大栗
	5 眼科専門医	2	阿部・中込
	6 産婦人科専門医	12	内田・須波・笠井・安田・福島・坂本・峰・野崎・大内・池田・望月・大和田
	7 耳鼻咽喉科専門医	3	平賀・霜村・森山
	8 泌尿器科専門医	2	保坂・横山仁
	9 形成外科専門医	2	小林公・梅澤
	10 病理専門医	1	小山
	11 総合内科専門医	16	宮下・柿崎・望月仁・中村・梅谷・佐野・牧野・井上正晴・若杉・温井・飯野・神崎・縄田・許山・三河・滝澤
	12 外科専門医	20	中込・飯室・宮坂・羽田・安留・古屋・井上正行・鷹野・後藤太・大竹・大矢知・津田・服部・井上潤・岩瀬史・河野・萩原・大森・沼野・横山毅
	13 救急科専門医	8	岩瀬史・井上潤・宮崎・松本・河野・柳沢・萩原・岩瀬弘
	14 小児科専門医	7	星合・反頭・後藤裕・齊藤・内藤・根本・長谷部
	15 脳神経外科専門医	2	中野・松本
	16 精神科専門医	2	渡辺・大内
	17 リハビリテーション専門医	0	
	18 臨床検査専門医	0	
	19 総合診療科専門医	0	
計		92	
サブスペ領域	1 糖尿病専門医	4	井上・若杉・齊藤・滝澤
	2 肝臓専門医	1	飯室
	3 感染症専門医	1	三河
	4 血液専門医	3	飯野・中島・山本
	5 循環器専門医	7	中村・梅谷・佐野・牧野・矢野・清水・星合
	6 呼吸器専門医	3	柿崎・筒井・小林
	7 消化器病専門医	11	細田・望月仁・小嶋・鈴木・大山・飯室・宮坂・羽田・安留・鷹野・大森
	8 腎臓専門医	4	神宮寺・若杉・温井・長沼
	9 内分泌代謝科専門医	2	柘津・滝澤

県立中央病院医師の専門性資格

専門医種類	人数	医師名
10 消化器外科専門医	5	飯室・羽田・安留・古屋・大森
11 超音波専門医	2	中村・須波
12 細胞診専門医	1	柿崎
13 透析専門医	4	神宮寺・若杉・温井・長沼
14 心臓血管外科専門医	2	中島・津田
15 呼吸器外科専門医	2	後藤太・大竹
16 消化器内視鏡専門医	8	細田・望月・小嶋・鈴木・大山・飯室・宮坂・安留
17 小児外科専門医	2	大谷知・小泉
18 リウマチ専門医	3	神崎・千野・佐久間
19 乳腺専門医	2	中込・井上正行
20 臨床遺伝専門医	1	須波
21 気管支鏡専門医	1	後藤太
22 核医学専門医	2	中村・遠山
23 大腸肛門病専門医	2	宮坂・安留
24 婦人科腫瘍専門医	1	坂本
25 熱傷専門医	1	岩瀬史
26 脳血管内治療専門医	1	松本
27 がん薬物療法専門医	3	飯野・中込・三河
28 周産期(新生児)専門医	6	内田・須波・笠井・内藤・根本・小泉
29 小児神経専門医	2	反頭・後藤
30 口腔外科専門医	1	高橋
31 不整脈専門医	2	梅谷・矢野
32 日本アフェレンス学会認定専門医	1	温井
33 食道外科学会専門医	1	羽田
34 内分泌・甲状腺外科専門医	1	井上正行
35 皮膚腫瘍外科指導専門医	1	小林公
36 日本外傷学会専門医	3	岩瀬史・岩瀬弘・井上潤
37 日本ロボット外科学会国内B級ロボット手術専門医	2	坂本・大森
38 小児循環器専門医	3	内藤・星合・小泉
39 日本臨床細胞学会専門医	1	小山
40 日本てんかん学会専門医	1	反頭
41 日本臨床神経生理学会専門医	1	後藤裕
42 集中治療専門医	2	柳沢・小泉
43 社会医学系専門医	3	笹本・井上潤・岩瀬史
44 日本呼吸器内視鏡学会専門医	1	柿崎
計	111	

サブスペ領域

合計

203

# 運営費負担金比率 (運営費負担金/経常収入)

	平成25年度	平成26年度	平成27年度	平成28年度	平成29年度
1	山口 10.8%	山口 10.6%	山口 10.2%	山口 10.0%	山口 9.6%
2	大阪 14.3%	大阪 13.7%	大阪 12.7%	大阪 10.1%	大阪 10.1%
3	山梨 16.8%	山梨 15.6%	山梨 14.8%	山梨 14.2%	山梨 14.2%
4	静岡 18.5%	静岡 17.4%	静岡 16.8%	静岡 16.2%	静岡 15.7%
5	秋田 20.5%	神奈川 21.0%	神奈川 20.1%	神奈川 19.1%	神奈川 17.8%
6	神奈川 22.0%	長野 22.9%	宮城 21.0%	宮城 20.2%	宮城 21.0%
7	長野 22.4%	秋田 22.8%	長野 24.0%	長野 23.8%	長野 23.8%
8	宮城 27.4%	宮城 27.3%	秋田 24.0%	秋田 23.7%	秋田 23.9%

# 経営分析比較

(平成29年度)

	医療収支比率	経常収支比率	実質経常収支比率	給与費比率	繰入金比率	減価償却比率
1	山梨 95.6%	山梨 108.5%	山梨 93.1%	山梨 46.3%	山口 9.6%	秋田 12.9%
2	大阪 93.0%	静岡 103.1%	山口 90.3%	大阪 51.6%	大阪 10.1%	長野 12.9%
3	山口 92.6%	長野 100.1%	大阪 89.6%	神奈川 57.4%	山梨 14.2%	神奈川 11.2%
4	静岡 86.3%	山口 99.8%	静岡 87.1%	山口 59.3%	静岡 15.7%	大阪 11.2%
5	神奈川 82.2%	大阪 99.7%	神奈川 79.1%	静岡 58.5%	神奈川 17.8%	山梨 10.0%
6	長野 78.6%	秋田 99.1%	宮城 76.8%	宮城 68.7%	宮城 21.0%	静岡 9.5%
7	宮城 75.0%	宮城 97.1%	秋田 75.5%	長野 73.3%	長野 23.8%	宮城 8.8%
8	秋田 67.0%	神奈川 96.3%	長野 78.8%	秋田 92.7%	秋田 23.9%	山口 7.9%

医療収支比率  
 経常収支比率  
 実質経常収支比率  
 給与費比率  
 繰入金比率  
 減価償却比率

:(入院+外来+その他の医療収入)/医療費用(減価償却含む)  
 :経常収入(繰入金含む)/経常費用  
 :経常収入(繰入金除く)/経常費用  
 :給与費/医療収益  
 :繰入金/経常収入  
 :減価償却費/医療収益

# 経営分析比較

## (平成28年度決算)

	医業収支比率	経常収支比率	実質経常収支比率	給与費比率	繰入金比率	減価償却比率
1	山梨 94.5%	山梨 107.6%	山梨 92.2%	山梨 46.2%	山口 10.0%	秋田 13.1%
2	山口 93.5%	静岡 102.5%	山口 91.1%	大阪 52.2%	大阪 10.1%	神奈川 12.4%
3	大阪 93.0%	山口 101.2%	大阪 89.8%	長野 58.1%	山梨 14.2%	山梨 12.0%
4	静岡 86.3%	秋田 100.9%	静岡 86.0%	神奈川 58.2%	静岡 16.2%	宮城 11.4%
5	神奈川 81.0%	大阪 99.8%	宮城 78.3%	山口 58.3%	神奈川 19.1%	長野 10.4%
6	長野 78.2%	長野 98.8%	神奈川 77.9%	静岡 59.5%	宮城 20.2%	大阪 9.7%
7	宮城 76.9%	宮城 98.1%	秋田 77.0%	宮城 67.2%	長野 23.8%	山口 9.1%
8	秋田 68.5%	神奈川 96.2%	長野 75.4%	秋田 90.6%	秋田 23.7%	静岡 8.7%

医業収支比率  
 経常収支比率  
 実質経常収支比率  
 繰入金比率  
 給与費比率  
 減価償却比率

: (入院+外来+その他医業収入)/医業費用(減価償却含む)  
 : 経常収入(繰入金含む)/経常費用  
 : 経常収入(繰入金除く)/経常費用  
 : 繰入金/経常収入  
 : 給与費/医業収益  
 : 減価償却費/医業収益

180702

2018/2/26 企画経理課 遠藤

4



# 経営分析比較

## (平成27年度)

	医療収支比率	経常収支比率	実質経常収支比率	繰入金比率	減価償却比率
1	山梨 92.5%	山梨 105.5%	山梨 89.9%	山口 10.2%	長野 13.8%
2	大阪 92.3%	静岡 102.9%	大阪 89.3%	大阪 12.7%	秋田 13.4%
3	山口 90.2%	大阪 102.3%	山口 87.6%	山梨 14.8%	山梨 13.3%
4	静岡 85.9%	長野 100.2%	静岡 85.6%	静岡 16.8%	宮城 13.0%
5	神奈川 83.1%	秋田 100.2%	長野 78.7%	神奈川 20.1%	神奈川 11.8%
6	長野 79.5%	神奈川 99.8%	神奈川 79.9%	宮城 21.0%	大阪 10.1%
7	宮城 75.6%	宮城 97.9%	宮城 77.3%	長野 24.0%	山口 9.0%
8	秋田 68.4%	山口 97.6%	秋田 76.2%	秋田 24.0%	静岡 8.5%

医療収支比率 : (入院+外来+その他医療収入)/医療費用(減価償却含む)

経常収支比率 : 経常収入(繰入金含む)/経常費用

実質経常収支比率 : 経常収入(繰入金除く)/経常費用

繰入金比率 : 繰入金/経常収入

減価償却比率 : 減価償却費/医療収益

# 経営分析比較

(平成26年度)

	経常収支比率	医業収支比率	繰入金比率	実質経常収支比率	減価償却比率
1	<u>山梨</u> 103.5%	山口 92.9%	山口 10.6%	山口 89.9%	<u>山梨</u> 14.9%
2	静岡 103.0%	<u>山梨</u> 89.5%	大阪 13.7%	<u>山梨</u> 87.3%	長野 14.3%
3	秋田 101.4%	大阪 88.5%	<u>山梨</u> 15.6%	大阪 85.6%	秋田 13.6%
4	山口 100.6%	静岡 85.4%	静岡 17.4%	静岡 85.1%	宮城 13.0%
5	宮城 100.0%	神奈川 81.8%	神奈川 21.0%	神奈川 78.8%	神奈川 12.3%
6	神奈川 99.8%	長野 79.7%	秋田 22.8%	秋田 78.3%	大阪 10.9%
7	長野 99.7%	宮城 76.2%	長野 22.9%	長野 76.9%	静岡 9.5%
8	大阪 99.2%	秋田 70.3%	宮城 27.3%	宮城 73.6%	山口 8.5%

医業収支比率  
 実質経常収支比率  
 経常収支比率  
 繰入金比率  
 減価償却比率

:(入院+外来+その他医業収入)/医業費用(減価償却含む)  
 :経常収入(繰入金除く)/経常費用  
 :経常収入(繰入金含む)/経常費用  
 :繰入金/経常収入  
 :減価償却費/医業収益

160726